loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Hidden Gem - Symbiotec Pharmalab: Transforming generic API business into complex extensions

ICICIdirect Research 09 Oct 2026 DISCLAIMER

Symbiotec Pharmalab is a fermentation-based API player focused on corticosteroid and steroidal-hormone APIs, with a global volume market share of ~30% in these segments. The company has invested ₹1,000+ crore over the past 3–4 years towards new growth businesses, including ~₹380 crore in Complex Injectables and ~₹585 crore in CDMO fermentation. 
In CDMO business, the company has multiple contracts with assured payment arrangements, including alternate-protein contracts with US and European customers and contracts for insulin/GLP-1 drug substances, providing good visibility on future revenues. 
Whereas in Complex injectables, the company has partnered with a global pharma player for roll out of its first two injectable products in the US. The milestone income for the same is expected in FY27E, while commercial revenues likely to commence from FY28E. 
The Complex Injectables business is forwarding integration of the company’s existing API capabilities, hence will have better unit economics, while the CDMO business is also expected to command higher margins than the legacy API business. 
With new modalities coming in, we estimate EBITDA margins can improve from ~27% currently to ~33% by FY29E whereas return profile to gradually improve to ~18% over the medium term. Besides this management has aspiration of 3x Revenue, 4x EBITDA in 5 Year time frame.   
We believe Symbiotec has the capabilities and investments required to transition from a legacy API manufacturer towards a more diversified complex API/CDMO-led business model, supported by strong revenue visibility, higher margins and improving returns. We initiate coverage with a BUY rating and a TP of ₹1,540/share based on 19x FY29E EBITDA.

 

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere